Cyteir Therapeutics Inc Stock (OTC: CYTT)

Latest news for Cyteir Therapeutics Inc (OTC:CYTT) Stock

Cyteir Therapeutics Inc

Cytta Corp

Jefferies analyst Christopher LeFemina maintains BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) with a Hold and lowers the price target from $57 to $53.

News

Price Target

Analyst Ratings

Jefferies Maintains Hold on BHP Group, Lowers Price Target to $53

Jefferies analyst Chris LaFemina maintains Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) with a Buy and lowers the price target from $60 to $48.

Jefferies Maintains Buy on Freeport-McMoRan, Lowers Price Target to $48

Bernstein on Monday outlined bold predictions for the cryptocurrency market in 2025, emphasizing Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) growth, regulatory changes and the convergence of <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40752428/crypto-set-to-dominate-ai-payments-bernstein-says">crypto with AI technologies</a>.
<h2 class="wp-block-heading">Bernstein&#8217;s 2025 Bitcoin Target</h2>
According to the report, Bitcoin is poised to <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42338347/bitcoin-to-emerge-as-premier-store-of-value-asset-hit-1-million-by-2033-says-bernstein">reach $200,000 by the end of 2025</a>, driven by rising institutional demand and its limited supply.
"Bitcoin's price trajectory reflects increased corporate treasuries and ETF holdings, making it a cornerstone of the financial future," it stated.
The report also highlights an anticipated surge in corporate Bitcoin investments, predicting treasury allocations will double to exceed $50 billion, up from $24 billion in 2024. 
This trend is led by industry pioneers such as MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), which continues to <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42723691/microstrategy-drops-209-million-on-bitcoin-in-8-week-buying-blitz">increase its holdings</a>.
"MicroStrategy remains the flagbearer, tapping new capital markets and significantly expanding Bitcoin reserves," Bernstein analysts noted.
<h2 class="wp-block-heading">Bitcoin ETFs To Continue Buying</h2>
The <a href="https://www.benzinga.com/25/01/42793495/bitcoin-surges-above-98000-defying-thursdays-record-etf-outflows">expansion of Bitcoin ETFs</a> is another key driver of growth, with net inflows expected to surpass $70 billion, doubling the $35 billion recorded in 2024.
Bernstein emphasized that ETF growth demonstrates rising institutional confidence in Bitcoin as a diversified investment vehicle.
<h2 class="wp-block-heading">Bitcoin Mining Meets AI Data Centers</h2>
The research predicts a transformative shift for Bitcoin miners, who are expected to allocate increasing power capacity toward <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42745169/bitcoin-reserves-spot-etfs-ai-agents-key-trends-to-watch-in-crypto-in-2025">AI data centers</a>.
This move is seen as both a sustainability strategy and a method to broaden institutional appeal. 
"This shift ensures sustainability and a broader institutional appeal," the report stated.
The convergence of cryptocurrency and artificial intelligence is set to redefine both sectors.
Bernstein envisions AI-enabled crypto functionalities driving innovation, from autonomous agents to decentralized markets for AI services. 
"The convergence of crypto and AI will redefine both industries," the report stated.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42709119/terra-luna-co-founder-do-kwon-to-be-extradited-to-the-us-report">Terra Luna Co-Founder Do Kwon To Be Extradited To The US: Report</a>
<h2 class="wp-block-heading">Stablecoin Regulation Coming</h2>
Bernstein foresees significant regulatory changes, including stablecoin legislation and <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42701446/crypto-industry-anticipates-policy-overhaul-under-trump-administration">clarified crypto market structures</a>, which could position the United States as a leader in crypto innovation.
The stablecoin market is projected to cross $500 billion in circulation by 2025, bolstered by regulatory clarity and its utility in cross-border business payments. 
"Regulatory clarity will drive stablecoin adoption in cross-border B2B payments," Bernstein predicted.
The report also anticipates a wave of crypto IPOs and the tokenization of equity markets as the SEC adopts a pro-crypto stance. 
Analysts believe this shift will enable private crypto firms to enter public markets, marking a pivotal moment for the industry. 
"This marks a turning point for private crypto firms entering public markets," the report stated.
<h2 class="wp-block-heading">TradFi Interest Could Fuel Ethereum Spike</h2>
Traditional financial institutions are also expected to introduce new trading, custody and active asset management products, further integrating crypto into traditional markets.
Bernstein's report predicts that Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) will regain institutional favor due to its deflationary model and utility-driven demand, positioning it as the second-most valued blockchain. 
"Ethereum's unique use cases and staking yields will make it a favorite for traditional investors," the analysts noted.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42708796/owning-bitcoin-is-digital-real-estate-says-anthony-pompliano">&#8216;Owning Bitcoin Is Digital Real Estate,&#8217; Says Anthony Pompliano</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Bitcoin To $200,000 As Crypto Enters 'Infinity Age' In 2025, Bernstein Predicts

This decision is associated with a strategic transformation in the Company's business focus, to wind down its Alico Citrus division, which holds the Company's citrus production operations, to focus on its long-term diversified land usage and real estate development strategy, due to increasing financial challenges from citrus greening disease and environmental factors for many seasons.
The Company currently estimates that it will incur charges of approximately $1.5 to $2.0 million in connection with the Workforce Reduction, primarily consisting of severance payments, employee benefits and related costs. The Company expects that the majority of these charges will be incurred in the second and third quarters of 2025.

ALCO

Alico Plans Reduction In Current Workforce By Up To 172 Employees - Filing

EYEN

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Regional Health Properties, Inc. ("Regional") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHE#NYSE">RHE</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHE#NYSE">RHE</a>) and SunLink Health Systems, Inc. ("SunLink") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSY#NYSE">SSY</a>) jointly announced today that they have entered into a definitive agreement and plan of merger (the "merger agreement"), pursuant to which SunLink will merge with and into Regional (the "merger") in exchange for the issuance of an aggregate of 1,410,000 shares of Regional common stock and 1,410,000 shares of Regional's newly-authorized Series D 8% Cumulative Convertible Redeemable Preferred Stock with a liquidation preference of $10 per share. The merger has been approved unanimously by each company's board of directors and completion of the transaction is subject to the receipt of the approvals of the shareholders of both Regional and SunLink, regulatory approvals and satisfaction of customary closing conditions.

Regional Health to Merge with SunLink in $10M Preferred Stock Deal

Canaccord Genuity analyst David Hynes initiates coverage on ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy rating and announces Price Target of $120.

Initiation

TTAN

Canaccord Genuity Initiates Coverage On ServiceTitan with Buy Rating, Announces Price Target of $120

Stifel analyst Parker Lane initiates coverage on ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy rating and announces Price Target of $120.

Stifel Initiates Coverage On ServiceTitan with Buy Rating, Announces Price Target of $120

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and lowers the price target from $7 to $5.

BTAI

Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

First lawsuit filed in U.S. Court of Appeals for the District of Columbia Circuit challenging violation of the Constitutional guarantee of due process and statutory procedural requirements, as well as unlawful political influence, and asking the court to set aside the CFIUS review process and President Biden's blocking order Second lawsuit filed in U.S. District Court for the Western District of Pennsylvania against Cleveland-Cliffs, Cliffs' CEO Lourenco Goncalves, and USW President David McCall for their illegal and coordinated actions aimed at preventing the transaction and attempting to undermine U. S. Steel's ability to compete and Nippon Steel's ability to provide American-made steel to American consumers Determined that these legal actions are the necessary path toward closing the transaction and delivering shared success for U. S. Steel employees, communities, shareholders, and customers
&nbsp;
Today's legal actions demonstrate Nippon Steel's and U. S. Steel's continued commitment to completing the Transaction – despite political interference with the CFIUS process and the racketeering and monopolistic conspiracies of Cleveland-Cliffs and USW President David McCall – for the benefit of all stakeholders, including U. S. Steel's shareholders, who will receive the agreed upon $55.00 per share upon the Transaction closing. We remain confident that the Transaction is the best path forward to secure the future of U. S. Steel – and we will vigorously defend our rights to achieve this objective."

Legal

Nippon Steel, U. S. Steel File Multiple Lawsuits In Response To Wrongful Interference With Proposed Acquisition Of U. S. Steel

Keybanc analyst Jeffrey Hammond downgrades Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) from Overweight to Sector Weight.

Downgrades

HAYW

Keybanc Downgrades Hayward Holdings to Sector Weight

Goldman Sachs has postponed its projection for gold prices to hit $3,000 per ounce, shifting the timeline from early 2026 to mid-2026. The investment bank adjusted its expectations from the Federal Reserve, as tighter-than-expected monetary policy would influence <a target="_blank" href="https://www.benzinga.com/topic/gold" rel="noreferrer noopener">gold prices</a>.
Goldman analysts Lina Thomas and Daan Struyven forecast gold to reach $2,910 per ounce by the end of the year. The bank's economists now anticipate 75 basis points of rate cuts in 2025, down from the previously expected 100 basis points.
"Opposing forces — lower speculative demand and structurally higher central bank buying — have effectively offset each other, keeping gold prices range-bound over the past few months," they said in a note per Bloomberg's <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-01-06/goldman-pushes-back-3-000-gold-forecast-on-fewer-us-rate-cuts" rel="noreferrer noopener">report</a>, attributing the long-term demand to central banks buying appetite.
"Looking ahead, we forecast monthly purchases to average 38 tons through mid-2026," they stated.
Gold delivered a <a target="_blank" href="https://www.benzinga.com/markets/commodities/24/12/42502069/gold-poised-for-its-best-year-in-a-decade-while-bitcoin-surges-analysts-eye-2025-as-a-golden-era-for-precious-metal-amid-michael-saylors-push-for-btc-as-a-reserve-asset" rel="noreferrer noopener">robust performance</a> in 2024, gaining 27% due to monetary easing, central bank purchases, and lingering inflation fears. However, the rally lost momentum in late 2024 as the U.S. dollar strengthened following the election-driven optimism.
Still, the U.S. is finding other ways to take advantage of higher-for-longer gold prices. President Joe Biden just approved the final permit for the Stibnite Project in Idaho, a mining initiative led by Perpetua Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) and backed by billionaire investor John Paulson.
This project could supply more than 35% of the U.S. demand for antimony, a critical mineral essential for solar panels, flame retardants and military equipment, while also producing around 450,000 ounces of gold annually.
Although the project cost around $1.3 billion in 2020, the final number will be higher. Accounted reserves include 148 million pounds of antimony and 6 million ounces of gold, and production is set for 2028.
Antimony prices surged in 2024, rising over 200% and over 40% in a single day after China issued an <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42294914/mp-materials-are-on-the-rise-today-whats-going-on" rel="noreferrer noopener">export ban</a> on December 3.&nbsp;However, extreme price volatility and control over the market (China accounted for 48% of<a target="_blank" href="https://www.csis.org/analysis/chinas-antimony-export-restrictions-impact-us-national-security" rel="noreferrer noopener"> global production</a> and 63% of U.S. imports in 2023) are risky for producers.
Thus, the dual output of gold and antimony offers financial resilience, reducing dependence and insulating the project from external price fluctuations.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42783039/kobold-metals-raises-537-million-targets-going-public-within-a-few-years" target="_blank" rel="noreferrer noopener">Bill Gates And Jeff Bezos Backed Mining Startup Raises $537 Million, Targets Going Public In Few Years</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Commodities

Media

AAAU

GLDM

IAUM

OUNZ

PPTA

SGOL

Goldman Sachs Delays $3,000 Gold Forecast, Sees Fewer Rate Cuts In 2025

Once the reductions in the workforce are completed, the Company anticipates that they will lead to a quarterly reduction in expenses of approximately&nbsp;$9 million to&nbsp;$11 million. The run rate savings do not reflect the aggregate expected costs to implement the Restructuring Plan.

SEDG

SolarEdge Currently Estimates To Recognize Pre-tax Charges To Its GAAP Results Of Approximately $3M - $5M Consisting Of Severance, Other One-time Termination Benefits, And Other Costs

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Rocket Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>)</h3>
<ul>
<li>On Dec. 11, Rocket Pharmaceuticals announced a $165 million upsized public offering of 13.2 million shares at $12.50 per share. The company's stock fell around 10% over the past month and has a <a href="https://www.benzinga.com/quote/RCKT">52-week low of $11.15</a>.</li>
<li>RSI Value: 26.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RCKT Price Action: Shares of Rocket Pharmaceuticals fell 1.3% to close at $12.56 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">latest RCKT news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="893" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18.png" alt="" class="wp-image-719464" style="width:556px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18-768x725.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure>
<h3 class="wp-block-heading">Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 13, Inovio Pharmaceuticals announced a public offering of 10 million shares for gross proceeds of $30 million.. The company's stock fell around 53% over the past month and <a href="https://www.benzinga.com/quote/INO">has a 52-week low</a> of $1.74.</li>
<li>RSI Value: 18.5</li>
<li>INO Price Action: Shares of Inovio Pharmaceuticals gained 7.7% to close at $1.96 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">trend in INO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="923" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19.png" alt="" class="wp-image-719466" style="width:677px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19-768x706.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Outlook Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>)</h3>
<ul>
<li>On Dec. 27, Outlook Therapeutics announced a year-over-year increase in FY24 EPS results. &#8220;Over the course of the past year, our team has continued to execute and progress the development of ONS-5010/LYTENAVA&#x2122; in Europe and the United States. Following the receipt of our first positive reimbursement decision worldwide for LYTENAVA&#x2122; from NICE in the United Kingdom, our team continues to make preparations for commercial launch in the UK and Germany, which is expected in the first half of calendar 2025,&#8221; commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. The company's stock fell around 72% over the past six months and has a 52-week <a href="https://www.benzinga.com/quote/OTLK">low of $0.87</a>.</li>
<li>RSI Value: 26.9</li>
<li>OTLK Price Action: Shares of Outlook Therapeutics gained 8.8% to close at $2.24 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">breakout in OTLK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20.png" alt="" class="wp-image-719469" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20-768x701.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42791037/delta-air-lines-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Top 3 Health Care Stocks That Could Blast Off This Month

"At this stage, we must reduce our operating expenses, even after the cost-cutting measures and reductions in force the Company has made over the past year. Unfortunately, our target cost structure requires a further reduction not only in spending but also in our headcount," the company said.
The reductions will affect all departments across the company, both within headquarters and in the regional teams. They will impact individuals who have made important contributions to SolarEdge over the years, and have brought expertise and depth to their respective fields.&nbsp;

SolarEdge Reveals Development Of Detailed Plan For 2025; Says Will Need To Separate From Approximately 400 Employees; Plans To Reduce Spend In Order To Reach Targets - Filing

FUBO

Bloomberg Reported Disney Nears Deal To Merge Hulu + Live Into Fubo

D. Boral Capital analyst Jason Kolbert initiates coverage on Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) with a Buy rating and announces Price Target of $23.

NNOX

D. Boral Capital Initiates Coverage On Nano X Imaging with Buy Rating, Announces Price Target of $23

Truist Securities analyst Terry Tillman initiates coverage on ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy rating and announces Price Target of $120.

Truist Securities Initiates Coverage On ServiceTitan with Buy Rating, Announces Price Target of $120

Throughout December 2024, the Company's average hashrate was 35.52 EH/s and average fleet efficiency was 18.06 J/Th, resulting in an average of 21.56 bitcoin mined daily. The single day high reached 22.46 bitcoin.&nbsp;
The Company sold 12.65 bitcoin during December 2024 at an average price of approximately $101,246 per bitcoin.

CLSK

CleanSpark Says It Mined 668 Bitcoin In December And 7,024 Bitcoin In 2024

Morgan Stanley analyst Stephen Grambling initiates coverage on Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Underweight rating and announces Price Target of $87.

Comments

Cyteir Therapeutics Inc

News

Latest news for Cyteir Therapeutics Inc (OTC:CYTT) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga